ACLARION, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.278 USD | -3.14% |
|
-8.79% | -91.31% |
| 26/02 | Top Midday Decliners | MT |
| 21/02 | Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 78K 6.51M | Sales 2025 * | - | Capitalization | 2.28M 190M |
|---|---|---|---|---|---|
| Net income 2024 * | -5M -417M | Net income 2025 * | -5M -417M | EV / Sales 2024 * | 29.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.24
x | P/E ratio 2025 * |
-0.53
x | Employees | 5 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.07% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.14% | ||
| 1 week | -8.79% | ||
| Current month | -7.36% | ||
| 1 month | -9.18% | ||
| 3 months | -84.11% | ||
| 6 months | -94.49% | ||
| Current year | -91.31% |
1 week
0.27
0.31
1 month
0.270.69
Current year
0.276.75
1 year
0.2725.60
3 years
0.2764.80
5 years
0.2764.80
10 years
0.2764.80
| Managers | Title | Age | Since |
|---|---|---|---|
Brent Ness
CEO | Chief Executive Officer | 57 | 15/21/15 |
John Lorbiecki
DFI | Director of Finance/CFO | 61 | 01/21/01 |
Ryan Bond
PRN | Corporate Officer/Principal | 52 | 15/21/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Wesemann
BRD | Director/Board Member | 67 | 01/16/01 |
Jeffrey Thramann
CHM | Chairman | 59 | 01/20/01 |
Stephen Deitsch
BRD | Director/Board Member | 52 | 21/22/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/24/15 | 0.278 | -3.14% | 458,972 |
| 14/24/14 | 0.287 | +0.95% | 339,211 |
| 13/24/13 | 0.2843 | +2.78% | 197,375 |
| 10/24/10 | 0.2766 | -7.74% | 390,309 |
| 09/24/09 | 0.2998 | -1.64% | 120,526 |
Delayed Quote Nasdaq, May 16, 2024 at 01:30 am IST
More quotes
Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. It has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. It uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.278
USD
Average target price
1.5
USD
Spread / Average Target
+439.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -91.31% | 2.35M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- ACON Stock